Yueshen Sun Selected Research

Moxisylyte (Thymoxamine)

1/2021

Alterations of Gut Microbiome and Serum Metabolome in Coronary Artery Disease Patients Complicated With Non-alcoholic Fatty Liver Disease Are Associated With Adverse Cardiovascular Outcomes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yueshen Sun Research Topics

Disease

1	Heart Failure 01/2022
1	Acute Coronary Syndrome 01/2021
1	Non-alcoholic Fatty Liver Disease 01/2021

Drug/Important Bio-Agent (IBA)

1	CalciumIBA 01/2022
1	Sarcoplasmic Reticulum Calcium-Transporting ATPasesIBA 01/2022
1	chitotrioseIBA 01/2021
1	prochlorazIBA 01/2021
1	Estradiol (Delestrogen)FDA LinkGeneric 01/2021
1	16S Ribosomal RNAIBA 01/2021
1	Moxisylyte (Thymoxamine)IBA 01/2021
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021
1	aristolochic acid I (aristolochic acid)IBA 01/2021
1	palmitoleic acidIBA 01/2021
1	triethanolamineIBA 01/2021
1	brofaromineIBA 01/2021

Therapy/Procedure

2	Therapeutics 01/2021 - 01/2021